We're increasing our Eli Lilly price target after another beat-and-raise quarter
The strength of its GLP-1 business suggests the stock still has more room to run.
Covered in this story
Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.